Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment

In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine and conventional third-line therapy to patients with colorectal cancer (CRC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.

Trial Details

NCT ID
NCT06751966
Phase
NA
Sponsor
The First Affiliated Hospital of Nanchang University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Combination Product: Conventional third-line therapy
  • Neoantigen-based peptide vaccine
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • Patients with histologically or cytologically confirmed CRC;
  • At least one measurable lesion;
  • Aged 18-70, regardless of gender;
  • Disease progression after standard second-line therapy, and more than 2 weeks since the end of the last antitumor treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →